Antipsychotic Mechanisms of mGluR Agonists in the MK-801 Model of Schizophrenia

mGluR 激动剂在 MK-801 精神分裂症模型中的抗精神病机制

基本信息

  • 批准号:
    8268507
  • 负责人:
  • 金额:
    $ 38.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-10 至 2014-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): N-methyl-D-aspartate receptor (NMDAR)-mediated glutamate transmission, along with dopamine (DA) and 3-aminobutyric acid (GABA) systems, has long been linked to schizophrenia, but all commonly prescribed antipsychotic agents act on DA receptors. Recent studies indicate that metabotropic glutamate receptor (mGluR) agonists reverse the behavioral effects of the NMDAR antagonist phencyclidine (PCP) and dizocilpine (MK-801) in animal models and in patients with schizophrenia. These studies suggest that mGluR2/3 receptor agonists have antipsychotic properties and may provide a new treatment of schizophrenia. This finding is exciting, but it raises some fundamental questions: Why do mGluR2/3 agonists have the same therapeutic efficacy as D2 receptor antipsychotic agents and by what mechanisms do mGluR2/3 agonists ameliorate behavior? We hypothesize that mGluR2/3 agonists restore the disrupted NMDAR function induced by the MK- 801 blockade by directly regulating the expression and trafficking of NMDAR subunits in the prefrontal circuitry. An integrated approach of in vivo pharmacologic agents, in vitro patch clamp recording, and molecular techniques will be used to test our hypothesis in the MK-801 animal model of schizophrenia. The proposed experiments will provide insights into the underlying mechanisms of mGluR regulation of NMDAR-mediated transmission and will contribute to a better understanding of how mGluR agonists reverse behavioral effects of NMDAR antagonists in animal models and of the underlying molecular pathophysiological characteristics and treatment of schizophrenia. PUBLIC HEALTH RELEVANCE: Recent studies indicate that mGluR agonists have antipsychotic properties and may provide a new treatment of schizophrenia. However, a fundamental question raised is what mechanisms the mGluR2/3 agonists use to ameliorate behaviors. This study will certainly provide insights into the cellular and molecular mechanisms involved in actions of mGluR agonists as potential antipsychotics.
描述(由申请人提供):N-甲基-D-天冬氨酸受体(NMDAR)介导的谷氨酸传递,沿着多巴胺(DA)和3-氨基丁酸(GABA)系统,长期以来一直与精神分裂症相关,但所有常用的抗精神病药物均作用于DA受体。最近的研究表明,在动物模型和精神分裂症患者中,代谢型谷氨酸受体(mGluR)激动剂逆转了NMDAR拮抗剂苯环己哌啶(PCP)和地佐环平(MK-801)的行为效应。这些研究表明,mGluR 2/3受体激动剂具有抗精神病特性,可能为精神分裂症提供新的治疗方法。这一发现令人兴奋,但它提出了一些基本问题:为什么mGluR 2/3激动剂具有与D2受体抗精神病药物相同的治疗效果,以及mGluR 2/3激动剂通过何种机制改善行为?我们假设mGluR 2/3激动剂通过直接调节前额回路中NMDAR亚基的表达和运输来恢复MK- 801阻断诱导的NMDAR功能中断。一个综合的方法,在体内药物,体外膜片钳记录,和分子技术将被用来测试我们的假设在MK-801精神分裂症动物模型。拟议的实验将提供深入了解的潜在机制mGluR调节NMDAR介导的传输,并将有助于更好地了解如何mGluR激动剂逆转行为的影响NMDAR拮抗剂在动物模型和潜在的分子病理生理学特征和治疗精神分裂症。公共卫生相关性:最近的研究表明,mGluR激动剂具有抗精神病特性,可能为精神分裂症提供新的治疗方法。然而,一个根本的问题是mGluR 2/3激动剂使用什么机制来改善行为。这项研究肯定会提供深入了解mGluR激动剂作为潜在的抗精神病药物的作用所涉及的细胞和分子机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wen-Jun Gao其他文献

Wen-Jun Gao的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wen-Jun Gao', 18)}}的其他基金

Corticothalamic control of social motivation
皮质丘脑控制社会动机
  • 批准号:
    10529968
  • 财政年份:
    2022
  • 资助金额:
    $ 38.24万
  • 项目类别:
Norepinephrine tunes prefrontal-thalamic circuitry to modulate avoidance behavior
去甲肾上腺素调节前额丘脑回路以调节回避行为
  • 批准号:
    10586051
  • 财政年份:
    2022
  • 资助金额:
    $ 38.24万
  • 项目类别:
Norepinephrine tunes prefrontal-thalamic circuitry to modulate avoidance behavior
去甲肾上腺素调节前额丘脑回路以调节回避行为
  • 批准号:
    10451927
  • 财政年份:
    2022
  • 资助金额:
    $ 38.24万
  • 项目类别:
Corticothalamic control of social motivation
皮质丘脑控制社会动机
  • 批准号:
    10661763
  • 财政年份:
    2022
  • 资助金额:
    $ 38.24万
  • 项目类别:
Behavioral effects of igsf9b in the prefrontal cortex
igsf9b 对前额皮质的行为影响
  • 批准号:
    10054717
  • 财政年份:
    2020
  • 资助金额:
    $ 38.24万
  • 项目类别:
Role of prefrontal cortical dopamine in aggression
前额皮质多巴胺在攻击行为中的作用
  • 批准号:
    9281915
  • 财政年份:
    2016
  • 资助金额:
    $ 38.24万
  • 项目类别:
Role of prefrontal cortical dopamine in aggression
前额皮质多巴胺在攻击行为中的作用
  • 批准号:
    9153019
  • 财政年份:
    2016
  • 资助金额:
    $ 38.24万
  • 项目类别:
HIV gp120 and Prefrontal Cortical Function
HIV gp120 和前额皮质功能
  • 批准号:
    8434874
  • 财政年份:
    2012
  • 资助金额:
    $ 38.24万
  • 项目类别:
HIV gp120 and Prefrontal Cortical Function
HIV gp120 和前额皮质功能
  • 批准号:
    8331029
  • 财政年份:
    2012
  • 资助金额:
    $ 38.24万
  • 项目类别:
Development of NMDAR hypofunction and cognitive deficits
NMDAR 功能减退和认知缺陷的发展
  • 批准号:
    8898214
  • 财政年份:
    2009
  • 资助金额:
    $ 38.24万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 38.24万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.24万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 38.24万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.24万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 38.24万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.24万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 38.24万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 38.24万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 38.24万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.24万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了